welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
A Device for Rapid, Painless, Bedside Muscle Evaluation of Children
study id #: NCT02340923
condition: Duchenne Muscular Dystrophy
The purpose of this protocol is to perform Electrical Impedance Myography (EIM) testing on healthy children and children with duchenne muscular dystrophy so as to develop a new, convenient tool for the office based assessment of children with a wide variety of neuromuscular conditions.
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: January 2015
estimated completion: June 2016
size / enrollment: 327
- Electrical Impedance Myography Measurements [ Time Frame: Baseline (all subjects) & 3 months, 6 months, 1 year for returning subjects only ]
Up to 11 muscles will be measured using EIM technology. These muscles include: Right Lateral Deltoid, Right Biceps, Right Triceps, Right Wrist Flexors, Right Wrist Extensors, Right Vastus Lateralis, Right Tibialis Anterior, Right Gastrocnemius, Right Gluteus Medius, Right Biceps Femoris, and Right Thoracic Parapinal.
• Age 0-18
• Genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member.
• Age over 18
• Presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular DystrophyThis study is being performed as a post-...
European Home Mechanical Ventilation RegistryThe European Home Mechanical Ventilation...
Stomatognathic function in Duchenne muscular dystrophy: a case-control studyAim: This study aimed to analyse electr...
DMD HUB: Expanding clinical trial capacity for Duchenne muscular dystrophy in the UKWith Duchenne muscular dystrophy (DMD) c...
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug ApplicationOn February 14, 2019, Sarepta Therapeuti...